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After its first use in clinic since 1960, oral administration of l-3,4-
dihydroxyphenylalanine (levodopa) remains the main treatment
for Parkinson’s disease (PD) patients. Although the vast majority
respond positively to treatment, a significant proportion of PD
patients develop daily fluctuations in mobility and troublesome
involuntary movements known as levodopa-induced dyskinesias
(LIDs). The time-to-onset and severity of this motor complica-
tion show large individual variability thus limiting the long-term
use of levodopa and clinical strategies aimed at reducing LIDs
manifestation. In the last few years, a considerable effort has been
made to understand the neurobiological basis of this motor com-
plication. In particular, recent evidence coming from human and
animal studies has strongly contributed to reduce the gaps in our
knowledge of LIDs pathogenesis.
The papers in this research topic highlight several themes rel-
evant to the understanding of the clinical and neurobiological
basis of LIDs. From a neuropsychological perspective, Pietracupa
et al. (1) have explored the clinical correlated of the poor aware-
ness of LIDs in PD patients; since the few studies conducted so
far have used different methods and different patient populations,
several hypotheses have been postulated, which suggest that sev-
eral possible mechanisms may be implicated. One of the most
recently proposed mechanisms emphasizes the role of propriocep-
tive and sensorimotor deficits associated with the impairment of
the posterior parietal-ponto-cerebellar pathways, as nicely tested
in a sample of PD patients with and without LIDs in the study by
Stevenson et al. (2). Furthermore, using a top-down approach, the
present topic firstly presents the latest neurophysiological findings
in human models obtained using neuroimaging techniques and
then moves toward cellular and molecular mechanisms of LIDs in
animal model.
Finlay et al. (3) systematically adopted this approach in review-
ing the recent literature with the scope to define a translation
strategy that can bridge animal studies (that allow to assess the
precise effects of drug treatment) with neuroimaging data on
humans. These authors also discussed the last evidence provided
by our works (4, 5), where we demonstrated that LIDs patients are
characterized by anatomical and functional abnormalities of the
prefrontal cortex involving the supplementary motor area (SMA)
and the inferior frontal cortex (IFC). This notion has been recently
confirmed by two independent groups investigating LIDs patients
during the ON phase of levodopa therapy (6, 7). In particular,
Herz et al. (6) investigated brain functional activity of LIDs dur-
ing a motor task, continuously for 45 min after levodopa intake
before the beginning of peak-dose dyskinesias. They found that
PD patients with dyskinesias display an immediate hypersensitiv-
ity of the SMA and putamen to levodopa. Moreover, abnormal
resting-state functional connectivity between the IFC and the
putamen was demonstrated in PD patients with LID at 60 min
after levodopa intake, consistent with the expected time peaks of
dyskinesia (7).
Beyond the multiple phenomenology of LIDs in PD patients,
further insights on the pathophysiology of hyperkinetic move-
ment disorders derive from studies conducted in patients with
idiopathic dystonia, tardive dyskinesia (TD), and Gilles de la
Tourette syndrome (GTS). Dystonia is a hyperkinetic movement
disorder characterized by sustained or intermittent muscle con-
tractions causing abnormal, often repetitive, movements, postures,
or both (8). The term TD referred to abnormal movements pro-
duced by the chronic exposure to dopamine receptor blocking
agents. GTS is a childhood-onset complex neurobehavioral disor-
der defined by motor and phonic tics, which can be often com-
plicated by comorbid conditions that could progress to behavioral
changes. Recent neuroimaging papers demonstrate the presence of
anatomical abnormalities involving the IFC in all these disorders
(9–11). That is, we have hypothesized a common pathophysio-
logical mechanism for all these hyperkinetic disorders, including
LIDs, based on the inability by specific prefrontal areas to sup-
press involuntary movements (12, 13). Accordingly, other papers
in this topic addressed this hypothesis (14, 15). Overviewing PET-
related findings,Alongi et al. (14) discussed how this neuroimaging
technique has demonstrated, both in idiopathic dystonia and
GTS, metabolic and neurotransmission abnormalities not lim-
ited to the cortico-striato-pallido-thalamo-cortical pathway and
also within the cerebello-thalamo-cortical network. Tessitore et al.
(15) highlight a similar application for fMRI technique in PD
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patients, mainly discussing the usefulness of resting-state con-
nectivity analysis. Blood oxygen level-dependent functional MRI
signal recorded while the subject lies at rest with eyes closed rep-
resents an important tool for understanding brain disorders in
patients with PD. Brain regions with similar functions have been
shown to display robust functional connectivity during rest, which
reflects the presence of direct and indirect anatomical pathways.
For this reason, these authors proposed that in the near future,
the practical application of this technique might provide a reliable
MRI biomarker for an early diagnosis of PD.
Involvement of cortical areas (motor areas and prefrontal cor-
tices) as well of the cerebellum in patients with LIDs has been also
suggested by transcranial magnetic stimulation (TMS) studies,
specifically using protocols to probe synaptic plasticity in humans
(7, 16, 17). In the current research topic, Kishore et al. (18) pro-
pose a pathophysiological model of LIDs in PD in which aberrant
impaired plasticity in the motor cortex might be sustained by
deficient cerebellar modulation of sensory afferents to the motor
cortex itself. In this comprehensive review, the authors outline
functional and anatomical studies on basal ganglia circuits and
their reciprocal connection with the cerebellum, as well the role of
dopamine on the basal ganglia, the cortical motor areas and the
cerebellum. The model proposed by Kishore et al. (18) allows to
understand why non-invasive cerebellar stimulation may be effi-
cacious in treating LIDs in PD (17). Notably, this notion parallels
the aforementioned involvement of cortico-cerebellar pathways in
the pathological processes of predictive motor control in LIDs (2).
The role of cortical areas such the IFC and the primary motor
cortex and well of the cerebellum in the generation of LIDs is a
novel concept supported by several recent studies reviewed in this
research topic. Nevertheless, the cortico-striato-pallido-thalamo-
cortical loop represents a critical network for the generation of
LIDs as supported by the long-term beneficial effect of ablative
surgery and deep brain stimulation (DBS) of the globus pallidus
internus (GPi) and the subthalamic nucleus (STN) (19). Accord-
ingly, one of the reviews of the present research topic is focused
on the role of stereotactic surgery as a powerful tool to treat LIDs
in PD (20). From ablative techniques (pallidotomy and subthala-
motomy) to DBS of the GPi and the STN, the authors discuss the
evidence for a direct anti-dyskinetic effect by techniques involving
the GPi or the anteromedial portion of the STN, likely by current
spreading to the pallido-thalamic bundle.
The current research topic is also enriched by three intrigu-
ing reviews related to the experimental models of LIDs. Animal
models provide the unique opportunity to investigate in depth the
molecular and cellular machinery involved in the pathophysiology
of LIDs. Cenci (21) provides a comprehensive overview of the pre-
synaptic mechanisms of LIDs, focusing on the central notion that
the breakdown of pre-synaptic dopaminergic homeostasis predis-
poses to large fluctuations in therapeutic levels of dopamine upon
treatment with levodopa (21). She also underlines the relevance
of molecular, physiological, and morphological changes at post-
synapatic level produced by dopaminergic denervation (21). One
of the main concepts addressed in this review is the role of sero-
tonin neurons in pathophysiological mechanisms of LIDs. Indeed,
during the past few years, an abundant literature has support the
hypothesis, although quite controversial, that LIDs may depend
upon dopamine release from serotonin neurons. This hypothesis
is the also the main subject of the review by Carta and Tronci
(22). These authors revised the experimental evidence pointing to
the role of serotonin neurons in producing dyskinesia, also dis-
cussing the clinical implications. Indeed, over the course of PD,
other cellular compartments can substitute the lost dopaminergic
neurons in mediating levodopa conversion to dopamine. In this
context, the serotonergic system has emerged, in recent years, as
a key player. In comparison to dopaminergic neurons, serotonin
neurons share the same enzymatic machinery required to convert
levodopa to dopamine and to store dopamine after exogenous
administration of levodopa. However, serotonin neurons lack a
feedback control mechanism able to fine-tune the synaptic lev-
els of dopamine. Carta and Tronci (22) propose that this form of
dopamine is released in an uncontrolled manner, leading to exces-
sive synaptic dopaminergic peaks, and contributing to swings in
synaptic dopaminergic levels following oral administration of lev-
odopa. Although the authors discuss the vast body of evidence
providing support for a major role of the serotonergic system in
the appearance of LIDs in animal model, they also point out how
clinical evidence for a role of serotonin modulation in attenuating
LIDs in PD patients are still scarce and generally disappointing.
With a different perspective, Morin and Di Paolo report rel-
evant studies investigating glutamate receptor subtypes in rela-
tion to motor complications in PD patients and 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys
(23). MPTP-lesioned primates are very useful to test potential
antidyskinetic and/or anti-parkinsonian pharmacological agents.
Glutamate receptors are reported to interact with numerous neu-
rotransmitters and neuromodulators implicated in the develop-
ment of LIDs including dopaminergic neurotransmission. The
authors put the accent on the evidence that nigrostriatal dener-
vation in PD leads to increased glutamatergic transmission in the
basal ganglia and that glutamate receptor stimulation is involved
in the pathogenesis of levodopa-induced motor complications in
PD and glutamate receptor subtypes, such as mGlu5 and NMDA
receptors, are potential selective targets for treatment of these
adverse effects.
In conclusion, the contributions included in this research topic
highlight the role of different cortical and subcortical areas as well
as of other neurotransmitters beyond dopamine in the patho-
physiology of LIDs. We hope that this research will stimulate new
thinking about neurobiological mechanisms of LIDs.
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